The Pursuit of Optimal Outcomes in Cancer Therapy in a New Age of Rationally Designed Target-Based Anticancer Agents

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

1997 • 5,683 citations

A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate.

1979 • 1,331 citations

Preoperative Staging of Non–Small-Cell Lung Cancer with Positron-Emission Tomography

2000 • 1,130 citations

Patient preferences for oral versus intravenous palliative chemotherapy.

1997 • 922 citations

A Gompertzian model of human breast cancer growth.

1988 • 685 citations

Rationale for the use of alternating non-cross-resistant chemotherapy.

1982 • 545 citations

Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development

1999 • 538 citations

Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts.

1993 • 430 citations

Antitumor Effects of Doxorubicin in Combination With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies

1993 • 422 citations

The Norton-Simon hypothesis revisited.

1986 • 415 citations

Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture.

1981 • 344 citations

Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction

1992 • 337 citations

Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test

1994 • 291 citations

Polylysine and CVIM Sequences of K-RasB Dictate Specificity of Prenylation and Confer Resistance to Benzodiazepine Peptidomimetic in Vitro

1995 • 285 citations

The Biologic Effects of C225, A Chimeric Monoclonal Antibody to the EGFR, on Human Prostate Carcinoma

1996 • 243 citations

Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer

1999 • 225 citations

Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones

1998 • 212 citations

Anticancer Agents Targeting Signaling Molecules and Cancer Cell Environment: Challenges for Drug Development?

1999 • 206 citations

There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.

1998 • 185 citations

The chemotherapy of lymphomas: looking back, moving forward--the Richard and Hinda Rosenthal Foundation award lecture.

1987 • 180 citations

The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy.

1988 • 180 citations

Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture.

2000 • 179 citations

Kinetic parameters and growth curves for experimental tumor systems.

1970 • 179 citations

Epidermal Growth Factor Receptor Family and Chemosensitization

1997 • 176 citations

Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies

1996 • 176 citations

Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells

1998 • 155 citations

Resistance of K-RasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells.

1996 • 152 citations

The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.

1996 • 150 citations

The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation

1996 • 150 citations

Patient noncompliance with self-administered chemotherapy

1990 • 143 citations

Conventional cancer therapy: promise broken or promise delayed?

1998 • 142 citations

Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects

2000 • 138 citations

Pharmaceutical research in molecular oncology

1994 • 134 citations

Randomized discontinuation trials: Utility and efficiency

1993 • 131 citations

2-[C-11]thymidine imaging of malignant brain tumors.

1999 • 126 citations

Growth Curve of an Experimental Solid Tumor Following Radiotherapy

1977 • 126 citations

Comparison of potential markers of farnesyltransferase inhibition.

2000 • 121 citations

Compliance with oral drug therapy in patients with hematologic malignancy.

1987 • 116 citations

Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.

2000 • 115 citations

Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism

1998 • 100 citations

Application of a New Multinomial Phase II Stopping Rule Using Response and Early Progression

2001 • 76 citations

Development of Target-Based Antineoplastic Agents

2000 • 75 citations

Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines.

1998 • 68 citations

Laboratory models: some historical perspective.

1986 • 59 citations

Patient compliance with oral chemotherapy as assessed by a novel electronic technique.

1992 • 58 citations

Translational research: walking the bridge between idea and cure--seventeenth Bruce F. Cain Memorial Award lecture.

1998 • 51 citations

Quality-Adjusted Survival After Treatment for Acute Myeloid Leukemia in Childhood: A Q-TWiST Analysis of the Pediatric Oncology Group Study 8821

1999 • 45 citations

Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.

1998 • 36 citations

New Molecular Targets for Cancer Therapy

1996 • 35 citations

The promise of molecular oncology

1998 • 29 citations

Clinical evaluation of biologically targeted drugs: Obstacles and opportunities

1998 • 26 citations

Variance and Sample Size Calculations in Quality‐of‐Life‐Adjusted Survival Analysis (Q‐TWiST)

2000 • 22 citations

30 Potentiation of radiation-induced breast cancer cell death by inhibition of epidermal growth factor family of receptors

1999 • 6 citations